Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by rtftech16on Mar 23, 2018 12:03pm
256 Views
Post# 27770421

Understand this

Understand thisWith these types of companies, In my opinion, the market works like this: You need to find a great company first. Once found, buy at a fair price. When something like the phase 2b news comes out and it pops you need to sell, take your capital and some profits and leave some profits in, once it goes back down when the hype is over (and it always does) then you buy back in at a fair price, then hold (and this could be years) until they build their business out and/or sell to the highest bidder. Building a business doesn't happen overnight and once people realize this thats when the stock goes down, and down, and down. Well thats great because if no bad news against their business model or product offerings have come out/changed for the worse, you've found a great company, and the share price is on sale, you have yourself a buying opportunity. Thats what I see here in the 0.30 - 0.50 range. The longer it takes for a buyout and/or marketing the completed product after phase 3 and regulatory reviews the lower it will go in my opinion. People don't like to wait and then they sell, thats just how it is. Learn to work within that and you'll be good. 
Bullboard Posts